Subscribe to our newsletter.
Unlocking the Power of Precision: Introducing CVD StripAssay T
Cardiovascular Diseases (CVD) are pervasive but often preventable. Atherosclerosis and venous thrombosis stand as two major manifestations of CVD, influenced by intricate interplays between genetics and environment. Unhealthy lifestyles combined with specific genetic variants can heighten atherosclerosis risk, encompassing genes involved in endothelial function, hyperlipidemia, hypertension, and inflammation.
Similarly, a blend of adverse factors like hormone intake, immobilization, surgery, or cancer, coupled with genetic variations in coagulation genes, can trigger venous thrombosis. The significance of testing for genetic variations and instituting proper prophylaxis cannot be overstated, contributing to reduced CVD risks.
The CVD StripAssay T, a testament to precision diagnostics, primarily targets Factor V (FV) mutations, making it a pivotal tool in assessing thrombophilia risk:
The CVD StripAssay T kit offers a comprehensive solution for precise diagnostics, comprising essential components for efficient testing. With its advanced methodology, the assay covers nine key mutations associated with cardiovascular disease, enhancing early intervention prospects and patient care.
In the realm of cardiovascular disease diagnosis, precision and early detection are paramount. The CVD StripAssay T by ViennaLab represents a groundbreaking tool for assessing genetic factors contributing to atherosclerosis and thrombosis risks. By targeting pivotal mutations, it empowers healthcare professionals to make informed decisions and initiate timely prophylactic measures, reducing the burden of CVD. With its comprehensive kit and advanced methodology, CVD StripAssay T serves as a vital asset in enhancing patient outcomes and promoting cardiovascular health.